

Press Release

Frankfurt am Main, May 23, 2025

2025 Annual General Meeting of Fresenius: Shareholders approve all agenda items

- Management Board and Supervisory Board approved by a large majority
- Dividend of 1.00 euro per share agreed
- Wolfgang Kirsch re-elected as Chairman of the Supervisory Board

At today's Annual General Meeting (AGM) in Frankfurt am Main, Germany, the shareholders of Fresenius SE & Co. KGaA approved the proposals of the General Partner and the Supervisory Board with a large majority.

The actions of the General Partner and the Supervisory Board in 2024 were approved by 99.66 percent and 97.36 percent respectively. 99.98 percent voted in favor of approving the annual financial statements. 95.83 percent of the shareholders approved the compensation report for the 2024 financial year and 99.37 percent approved the dividend proposal of 1.00 euro per share. The resolutions on the remuneration for the members of the Supervisory Board and extending the authorization to hold virtual annual general meetings were also adopted with large majorities. 77.93 percent of the share capital was represented at the AGM.

Following the AGM, the newly appointed Supervisory Board of Fresenius SE & Co. KGaA re-elected Wolfgang Kirsch as its chair during its constituent meeting. Michael Diekmann and Grit Genster were also confirmed as deputy chairs and Susanne Zeidler was confirmed as chair of the Audit Committee. The shareholders previously re-elected Prof. Dr. Iris Löw-Friedrich and Dr. Christoph Zindel to the Supervisory Board in addition to Kirsch, Diekmann, and Zeidler. After 14 years in office, Prof. Dr. med. D. Michael Albrecht stepped down from the Supervisory Board. The AGM elected Prof. Dr. Ralf Kiesslich, Chairman of the Board of the University Medical Centre in Mainz, as his successor. The six employee representatives had already been elected beforehand. All Supervisory Board members were appointed for the period until the end of the 2029 AGM.

The new Supervisory Board of Fresenius SE & Co. KGaA comprises the following members:

Wolfgang Kirsch (Chairman)
Michael Diekmann (Deputy Chair)
Grit Genster (Deputy Chair)
Bernd Behlert
Tania Lara Campaña
Carsten Georg
Prof. Dr. Ralf Kiesslich
Prof. Dr. Iris Löw-Friedrich
Holger Michel
Oscar Romero de Paco
Susanne Zeidler
Dr. Christoph Zindel

* * *

Press Contact

Timo Lindemann
Corporate Communications
Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg, Germany
T +49 (0) 151 15515324
timo.lindemann@fresenius.com

About Fresenius

Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In the 2024 fiscal year, Fresenius generated €21.5 billion in annual revenue. Fresenius currently counts over 176,000 employees. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as an investment in Fresenius Medical Care. With around 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year. Fresenius Kabi's product portfolio touches the lives of 450 million patients annually and includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and intravenous generic drugs and fluids. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people's health. The largest shareholder is the non-profit Else Kröner-Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.

For more information visit the Company's website at www.fresenius.com
Follow us on social media: www.fresenius.com/socialmedia

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA

Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852

Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE

Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673

Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser

Chairman of the Supervisory Board: Wolfgang Kirsch